Bid for mylan. The price tag 40 billion, the largest potential takeover in the drug industry this year. The shares of mylan soared 8 and the shares for teva were higher. This could change the landscape of the industry but there is no guarantee anything about it will be easy. Megan tirrell has more. Another day and another deal in the drug industry. Nevas offer for rival mylan comes on the heels of mylans offer to buy periggo, a move some expected to be defensive. It contributed to deal activity among drug companies. You have to be big or you will get acquired. But mylan is not expected to go easily. Y rejected the idea of a merger with teva saying it will be a cultural clash and could raise antitrust concerned and teva dismissed that today and said they could close the deal by the end of the year. The Israeli Company said they could create a transformative generic drug company with revenue of 30 billion and there could be 2 billion in cost cuts it anticipated. Teva makes the multiple s
Bid for mylan. The price tag 40 billion, the largest potential takeover in the drug industry this year. The shares of mylan soared 8 and the shares for teva were higher. This could change the landscape of the industry but there is no guarantee anything about it will be easy. Megan tirrell has more. Another day and another deal in the drug industry. Nevas offer for rival mylan comes on the heels of mylans offer to buy periggo, a move some expected to be defensive. It contributed to deal activity among drug companies. You have to be big or you will get acquired. But mylan is not expected to go easily. Y rejected the idea of a merger with teva saying it will be a cultural clash and could raise antitrust concerned and teva dismissed that today and said they could close the deal by the end of the year. The Israeli Company said they could create a transformative generic drug company with revenue of 30 billion and there could be 2 billion in cost cuts it anticipated. Teva makes the multiple s
Bid for mylan. The price tag 40 billion, the largest potential takeover in the drug industry this year. The shares of mylan soared 8 and the shares for teva were higher. This could change the landscape of the industry but there is no guarantee anything about it will be easy. Megan tirrell has more. Another day and another deal in the drug industry. Nevas offer for rival mylan comes on the heels of mylans offer to buy periggo, a move some expected to be defensive. It contributed to deal activity among drug companies. You have to be big or you will get acquired. But mylan is not expected to go easily. Y rejected the idea of a merger with teva saying it will be a cultural clash and could raise antitrust concerned and teva dismissed that today and said they could close the deal by the end of the year. The Israeli Company said they could create a transformative generic drug company with revenue of 30 billion and there could be 2 billion in cost cuts it anticipated. Teva makes the multiple s